Gilead Sciences (GILD): Buy, Hold, or Sell in 2025?
AI-powered insights updated on 8/29/2025.
AI Signal: HOLD
GILD's momentum is mixed; EU approval of HIV prevention shot boosts news sentiment, but technicals show weakening trend strength. Fundamentals and earnings tone are moderately bullish.
E U Approval
Positive catalyst with twice-yearly HIV shot
Revenue Growth
Modest 2% YoY growth
M A C D Histogram
Consistently negative in August
Full Analysis Breakdown
Expand the sections below for a detailed look at our analysis.
Go Beyond the Analysis
Get real-time insights, compare stocks, and chat with our AI analyst on the interactive dashboard.
Disclaimer
The information provided on this page is for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other sort of advice and you should not treat any of the page's content as such. ProfitScout does not recommend that any cryptocurrency should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions.